Clinical Trial Update: Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing SYSA1901 to Perjeta in HER2-positive breast cancer is underway, with the status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Perjeta (pertuzumab)
• SYSA1901

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: HER2-positive Breast Cancer | Phase 3 | Status: UNKNOWN